Pharmaceutical Executive-04-21-2009

Trending on PharmExec

FDA Approves Subcutaneous Induction for Skyrizi in Crohn's Disease

Treasury Proposes Rules Adding Biotechnology to Outbound Investment Security Program

Pharmaceutical Executive Daily: Treasury Issues Notice to Add Biotech into Proposed COINS Act

FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B

Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche